Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Merger or Acquisition (October 2025)
8 slides from Novo Nordisk A/s Class B's merger presentation, Oct 9, 2025
Slide 1: Novo Nordisk – a focused healthcare company
Novo Nordisk – a focused healthcare company Novo Nordisk to acquire Akero Therapeutics Inc. RAFAEL VALVERDE Rafael lives with obesity Mexico
Slide 2: Forward-looking statements
2 Investor presentation 9 October 2025 Novo Nordisk® Forward-looking statements Novo Nordisk’s statutory Annual Report 2024, Form 20-F, any quarterly financial reports, investor presentations and written information released, shown, or oral statements made, to the public in the future by or on behal
Slide 3: Acquisition enhances Novo Nordisk's portfolio within Diabetes, Obesity and related comorbidities
3 Investor presentation 9 October 2025 Novo Nordisk® Acquisition enhances Novo Nordisk’s portfolio within Diabetes, Obesity and their related comorbidities Acquisition of Akero aligned with Novo Nordisk’s strategy Patient overlap between Novo Nordisk core therapy areas and MASH UNITED STATES ONLY Ty
Slide 4: Significant residual unmet need remains for therapeutic intervention in later disease stages
4 Investor presentation 9 October 2025 Novo Nordisk® Significant residual unmet need remains for therapeutic intervention in later disease stages MASH is a progressive disease, with >250 million people affected Potential for complementary portfolio across MASH disease stages globally and prevalence
Slide 5: Efruxifermin is a potential best-in-class FGF21 analogue for the treatment of MASH
5 Investor presentation 9 October 2025 Novo Nordisk® Efruxifermin is a potential best-in-class FGF21 analogue for the treatment of MASH Improvement in fibrosis with no worsening of MASH at 96 Efruxifermin (EFX) is a long-acting FGF21 analogue weeks in SYMMETRY phase 2b trial (F4) • Prolonged half-li
Slide 6: Phase 3 clinical development programme on-going to deliver on the potential of efruxifermin
6 Investor presentation 9 October 2025 Novo Nordisk® Phase 3 clinical development programme on-going to deliver on the potential of efruxifermin SYNCHRONY phase 3 development programme On-going SYNCHRONY phase 3 programme • Trials ongoing with readouts expected over coming years SYNCHRONY Primary en
Slide 7: Closing remarks
7 Investor presentation 9 October 2025 Novo Nordisk® Closing remarks Acquisition in line with strategy of developing innovative treatments in areas of diabetes, obesity and associated comorbidities Significant unmet need across MASH stages, in particular for patients living with cirrhosis (F4) EFX i
Slide 8: Investor contact information
09 October 2025 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen Novo Nordisk A/S under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Investor Relations Exchange under the symbol ‘NVO’.